PROGRAM CHAIR AND SPEAKER FACULTY
Arjun Balar, MD
Associate Professor of Medicine
Director – Genitourinary Medical Oncology Program
Medical Director – Clinical Trials Office
Laura and Isaac Perlmutter Cancer Center
New York, NY
PROGRAM OVERVIEW
This activity will cover the treatment and management of patients locally-advanced or metastatic urothelial carcinoma.
TARGET AUDIENCE
This activity is designed to meet the educational needs of urologists, medical/genitourinary oncologists, surgeons, and other health care professionals (primary care physicians, physicians-in-training, urology nurses, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with locally-advanced or metastatic urothelial cancer.
LEARNING OBJECTIVES
On completing the program, attendees should be able to:
- Develop treatment plans that appropriately sequence chemotherapy and immunotherapy in patients with locally-advanced or metastatic urothelial carcinoma (UC)
- Evaluate evidence for the use of maintenance immunotherapy as first-line therapy for metastatic UC
- Identify patients with locally-advanced or metastatic UC who are candidates for second-line treatment
- Apply current recommendations and emerging evidence regarding the use of immunotherapies for the management of locally-advanced UC during the COVID-19 pandemic, including the management of immune-related adverse events
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved and/or interested in the therapeutic management of patients with locally-advanced or metastatic urothelial carcinoma.
CNE Credits: 1.0 ANCC Contact Hour
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Faculty Member | Disclosure |
|---|---|
| Arjun Balar, MD | Dr. Balar reports that he serves as a consultant/advisor for Genentech, Incyte, Janssen, Merck, Pfizer, AstraZeneca/Medimmune, Nektar, Seattle Genetics, and Immunomedics. He has also done contracted research for Genentech, Nektar, Merck, AstraZeneca/MedImmune, Seattle Genetics, and Immunomedics. Dr. Balar has done speaking engagements for Genentech, Merck, and AstraZeneca/Medimmune. He has served on Steering Committees/Scientific Advisory Committees for Merck and Nektar. He receives equity and serves as a Scientific Advisory Board Member for EpiVax Oncology. |
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Angela L. Davis, PhD, Director of Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete posttest and evaluation form online.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: April 30, 2021
EXPIRATION DATE: April 30, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
